{"id":"tdv","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TDV reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is associated with several potential benefits, including improved glycemic control and weight loss.","oneSentence":"TDV is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:49.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07047521","phase":"PHASE3","title":"A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-11-07","conditions":"Dengue Fever","enrollment":496},{"nctId":"NCT06579755","phase":"PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-20","conditions":"Dengue Fever","enrollment":800},{"nctId":"NCT03498001","phase":"NA","title":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2018-04-16","conditions":"Type II Diabetes","enrollment":42},{"nctId":"NCT06741683","phase":"PHASE2, PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-31","conditions":"Dengue Fever","enrollment":187},{"nctId":"NCT06060067","phase":"PHASE3","title":"A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Healthy Volunteers","enrollment":480},{"nctId":"NCT02747927","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-26","conditions":"Healthy Volunteers","enrollment":20099},{"nctId":"NCT03746015","phase":"PHASE2","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-12-28","conditions":"Dengue Fever","enrollment":30},{"nctId":"NCT06843226","phase":"","title":"A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-05","conditions":"Dengue Fever","enrollment":70000},{"nctId":"NCT06665035","phase":"PHASE3","title":"A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-06-16","conditions":"Dengue Fever","enrollment":212},{"nctId":"NCT07054047","phase":"NA","title":"Improving Diagnosis and Treatment for Patients With Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-07-01","conditions":"GI Cancer","enrollment":438},{"nctId":"NCT03999996","phase":"PHASE3","title":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-11-12","conditions":"Dengue Fever","enrollment":365},{"nctId":"NCT02948933","phase":"","title":"Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-12-14","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":30000},{"nctId":"NCT02948829","phase":"PHASE2","title":"Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-03","conditions":"Healthy Volunteers","enrollment":200},{"nctId":"NCT04313244","phase":"PHASE3","title":"Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-05-15","conditions":"Dengue Fever","enrollment":614},{"nctId":"NCT04023708","phase":"","title":"Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-03-11","conditions":"Dengue Virus Infection","enrollment":104},{"nctId":"NCT03803618","phase":"","title":"Dengue Effectiveness Study in the Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2017-09-01","conditions":"Dengue, Severe Dengue, Virologically Confirmed Dengue","enrollment":2081},{"nctId":"NCT04846738","phase":"","title":"Transcranial Doppler and Quantitative Pupillometry as Neurological Prognostic Factors in Brain Damaged Patients Admitted to Intensive Care Unit","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-04-01","conditions":"Brain Damage","enrollment":73},{"nctId":"NCT01511250","phase":"PHASE2","title":"Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11-16","conditions":"Healthy","enrollment":360},{"nctId":"NCT04095429","phase":"NA","title":"Expect Respect Middle School Randomized Trial","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2019-10-03","conditions":"Adolescent Behavior, Violence in Adolescence, Group, Peer","enrollment":635},{"nctId":"NCT03525119","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-05-16","conditions":"Healthy Volunteers","enrollment":900},{"nctId":"NCT03771963","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-03-28","conditions":"Dengue Fever","enrollment":200},{"nctId":"NCT03423173","phase":"PHASE3","title":"Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-12","conditions":"Dengue Fever","enrollment":923},{"nctId":"NCT03342898","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-28","conditions":"Dengue","enrollment":900},{"nctId":"NCT03960385","phase":"","title":"Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2017-08-01","conditions":"Dengue","enrollment":1854},{"nctId":"NCT02302066","phase":"PHASE2","title":"Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-12-05","conditions":"Dengue Fever","enrollment":1800},{"nctId":"NCT02425098","phase":"PHASE2","title":"Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-03","conditions":"Dengue Fever","enrollment":351},{"nctId":"NCT03341637","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-12-14","conditions":"Dengue","enrollment":400},{"nctId":"NCT01728792","phase":"PHASE1","title":"Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-01-22","conditions":"Dengue Fever","enrollment":80},{"nctId":"NCT01765426","phase":"PHASE1","title":"Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-02-15","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT02193087","phase":"PHASE2","title":"Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-08-06","conditions":"Dengue Fever","enrollment":1002},{"nctId":"NCT01542632","phase":"PHASE1","title":"A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-02-01","conditions":"Healthy","enrollment":140},{"nctId":"NCT02997852","phase":"NA","title":"Biobehavioral Effects of Therapy Dog Visitation in Elderly Intensive Care Unit Patients: A Pilot and Feasibility Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-07-25","conditions":"Psychosocial Stress","enrollment":15},{"nctId":"NCT01224639","phase":"PHASE1","title":"Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever","status":"COMPLETED","sponsor":"Inviragen Inc.","startDate":"2010-10-11","conditions":"Dengue Fever","enrollment":96},{"nctId":"NCT03482687","phase":"NA","title":"It's Your Game: An Innovative Approach to Preventing Teen Dating Violence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-09","conditions":"Adolescent Behavior, Interpersonal Relationships, Domestic Violence","enrollment":834},{"nctId":"NCT03017027","phase":"NA","title":"Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-03","conditions":"Psychosocial Stress","enrollment":53}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CD4 LYMPHOCYTES ABNORMAL"},{"count":1,"reaction":"CD4 LYMPHOCYTES INCREASED"},{"count":1,"reaction":"DRUG RESISTANCE"},{"count":1,"reaction":"GENITAL HERPES"},{"count":1,"reaction":"HERPES SIMPLEX"},{"count":1,"reaction":"IMMUNE RECONSTITUTION SYNDROME"},{"count":1,"reaction":"VIRAL LOAD INCREASED"}],"_approvalHistory":[],"publicationCount":533,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-003","DENVax","QDENGA"],"phase":"phase_3","status":"active","brandName":"TDV","genericName":"TDV","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TDV is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2022-12-05T00:00:00.000Z","mah":"Takeda Pharmaceuticals International AG Ireland Branch","brand_name_local":"Qdenga","application_number":"EMEA/H/C/005155"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}